Suzhou Novartis Pharma Technology Maps Out Next Year’s Investment Plan
This article was originally published in PharmAsia News
Executive Summary
Suzhou Novartis Pharma Technology, Novartis' investment in China focusing on R&D and production of patented active pharmaceutical ingredients, recently disclosed that it began Phase 1 trials in October. Since beginning operations early this year, the company's analytical chemistry and R&D center has brought in almost 100 local and overseas experts, engineers and researchers to develop and synthesize Novartis' innovative raw ingredients. Even during the current global economic recession, Suzhou Novartis is still adhering to its original plan of investing $50 million next year for Phase II and III projects. With a long-term development view in China, it will further pump in $30 million to expand its R&D center, adding new equipment and staff. (Click here for more - Chinese Language)
You may also be interested in...
Post-Brexit UK Risks Being ‘Left Out In The Cold’ As EU Coordinates Action On Shortages
The UK is not alone in experiencing drug shortages, as data from across Europe show, but its departure from the EU makes it more difficult to respond to supply chain pressures, according to new research.
Dr Reddy’s Knocked Back On Rituximab In US
Dr Reddy’s has received a complete response letter from the US FDA, knocking back its proposed rituximab biosimilar rival to Rituxan.
Sandoz And Samsung Celebrate Stelara Rival’s EU Approval
Sandoz and Samsung Bioepis have received final European Commission approval for their partnered Pyzchiva biosimilar rival to Stelara. But with European competition on ustekinumab due to kick off in just a matter of months, further applicants are also waiting in the wings.